natgillin/translations-raw huggingface dataset:
Ilaris is used in adults to treat the symptoms of frequent gouty arthritis attacks if other treatments have not worked well enough. 
Ilaris se primjenjuje kod odraslih osoba za liječenje simptoma učestalih napada uričnog artritisa ako ostale terapije nisu dovoljno dobro djelovale.
If a patient becomes neutropenic or leukopenic, the WBC counts should be monitored closely and treatment discontinuation should be considered. 
Ako se kod bolesnika javi neutropenija ili leukopenija, broj Lkc treba pažljivo kontrolirati te razmotriti prekid liječenja.
There were no antibodies against Ilaris observed in TRAPS, HIDS/MKD and FMF patients treated with doses of 150 mg and 300 mg over 16 weeks of treatment. 
Nije bilo protutijela protiv Ilarisa opaženih u bolesnika s TRAPS-om, HIDS/MKD-om i FMF-om liječenih dozama od 150 mg i 300 mg tijekom 16 tjedana liječenja.
Gouty arthritis is caused by the formation of urate crystals. 
Urični artritis je uzrokovan stvaranjem kristala urata u tijelu.
Carefully withdraw the required volume depending on the dose to be administered (0.1 ml to 1 ml) and subcutaneously inject using a 27 G x 0.5 inch (13 mm) needle. 
Pažljivo izvucite potreban volumen ovisno o dozi koju treba primijeniti (0,1 ml do 1 ml) i injicirajte supkutano koristeći iglu od 27 G x 13 mm.
Never re-use the leftover solution. 
Nikada nemojte ponovno upotrebljavati preostalu otopinu.
Overall, 33% (25/75) of patients randomised to dose reduction or dose interval prolongation arms were able to discontinue treatment with canakinumab and maintain inactive disease status for 6 months. 
Općenito, 33% (25/75) bolesnika randomiziranih na smanjenje doze ili produljenje intervala doziranja uspjeli su prekinuti liječenje kanakinumabom i održati status neaktivne bolesti 6 mjeseci.
Significant improvements were seen in physician's clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient's assessment of symptoms. 
Značajna poboljšanja uočena su u liječnikovoj kliničkoj procjeni aktivnosti autoinflamatorne bolesti: ukupna procjena aktivnosti autoinflamatorne bolesti, procjena kožne bolesti (urtikarijski kožni osip), artralgija, mijalgija, glavobolja/migrena, konjunktivitis, umor/malaksalost, procjena drugih povezanih simptoma i bolesnikova procjena simptoma.
Use of canakinumab with TNF inhibitors is not recommended because this may increase the risk of serious infections. 
Primjena kanakinumaba s inhibitorima TNF-a ne preporučuje se zato što bi mogla povećati rizik od ozbiljnih infekcija.
- Keep this medicine out of the sight and reach of children. 
Lijek čuvajte izvan pogleda i dohvata djece.
After repeated subcutaneous administration of 150 mg every 4 weeks, canakinumab minimal concentration at week 16 (Cmin) was estimated to be 15.4 ± 6.6 g/ml. 
Nakon ponovljene supkutane primjene 150 mg svaka 4 tjedna, procijenjeno je da minimalna koncentracija kanakinumaba u 16. tjednu (Cmin) iznosi 15,4 ± 6,6 g/ml.
No data are available on the risk of secondary transmission of infection by live (attenuated) vaccines in patients receiving canakinumab. 
Nema dostupnih podataka o riziku od sekundarnog prijenosa infekcije živim (atenuiranim) cjepivima kod bolesnika koji primaju kanakinumab.
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still's disease. 
Sindrom aktivacije makrofaga (engl. macrophage activation syndrome; MAS) poznat je, po život opasan poremećaj koji se može razviti u bolesnika s reumatskim bolestima, osobito Stillovom bolešću.
Of the patients in clinical remission who continued with further dose reduction (1 mg/kg every 4 weeks) or dose interval prolongation (4 mg/kg every 12 weeks), 93% (26/28) and 91% (30/33) of patients, respectively, were able to maintain inactive disease status for 6 months. 
Od bolesnika u kliničkoj remisiji koji su nastavili s dodatnim smanjenjem doze (1 mg/kg svaka 4 tjedna) ili produljenjem intervala doziranja (4 mg/kg svakih 12 tjedana), 93% (26/28), odnosno 91% (30/33) bolesnika uspjelo je održati status neaktivne bolesti 6 mjeseci.
Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators. 
Kanakinumab se veže visokim afinitetom specifično za humani IL-1 beta i neutralizira biološku aktivnost humanog IL-1 beta tako što blokira njegovu interakciju s receptorima za IL-1 te tako sprječava aktivaciju gena koju inducira IL-1 beta i stvaranje upalnih posrednika.
Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks (see section 4.5). 
Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom, osim ako koristi očigledno ne premašuju rizike (vidjeti dio 4.5).
Formal carcinogenicity studies have not been conducted with canakinumab. 
Formalna ispitivanja kancerogenosti nisu se provodila s kanakinumabom.
Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks. 
Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom osim ako je jasno da koristi premašuju rizike.
The mean change in pain score among canakinumab treated patients was consistent at day 29. 
Srednja promjena u rezultatu za bol među bolesnicima liječenim kanakinumabom bila je dosljedna nakon 29 dana.
The most frequent adverse drug reactions were infections predominantly of the upper respiratory tract. 
Najučestalije nuspojave na lijek bile su infekcije pretežno gornjeg dijela dišnog sustava.
Concomitant use of canakinumab with tumour necrosis factor (TNF) inhibitors is not recommended because this may increase the risk of serious infections (see section 4.5). 
Istodobna primjena kanakinumaba s inhibitorima tumor nekrotizirajućeg faktora (TNF) se ne preporučuje jer bi to moglo povećati rizik od ozbiljnih infekcija (vidjeti dio 4.5).
It is not known whether Ilaris passes into human milk. 
Nije poznato izlučuje li se Ilaris u majčino mlijeko.
Although reductions in platelet count (≥ Grade 2) occurred in 0.6% of patients, bleeding has not been identified as an adverse reaction. 
Iako su se smanjenja broja trombocita (≥ stupnja 2) javila u 0,6% bolesnika, krvarenje nije utvrđeno kao nuspojava.
The incidence of patients with triglyceride elevations > 5 x upper limit of normal (ULN) was 2.4% with canakinumab and 0.7% with triamcinolone acetonide. 
Incidencija bolesnika s povišenjima triglicerida >5 x gornja granica normale (GGN) bila je 2,4% s kanakinumabom i 0,7% s triamcinolon acetonidom.
Experience from individual patients who achieved a complete response following dose escalation to 600 mg (8 mg/kg) every 8 weeks suggests that a higher dose may be beneficial in patients not achieving complete response or not maintaining complete response with the recommended doses (150 mg or 2 mg/kg for patients ≥ 15 kg and ≤ 40 kg). 
Iskustvo s pojedinačnim bolesnicima koji su postigli potpuni odgovor nakon povećanja doze na 600 mg (8 mg/kg) svakih 8 tjedana upućuje na to da bi viša doza mogla biti korisna kod bolesnika koji ne postignu potpun odgovor ili ne održavaju potpun odgovor s preporučenim dozama (150 mg ili 2 mg/kg za bolesnike ≥15 kg i ≤40 kg).
- Any unused medicine must be discarded after the dose has been injected. 
Sav neiskorišteni lijek mora se baciti nakon ubrizgavanja doze.
Gouty arthritis There is no relevant use of Ilaris in the paediatric population in the indication gouty arthritis. 
Urični artritis Nema relevantne primjene Ilarisa u pedijatrijskoj populaciji u indikaciji uričnog artritisa.
The active substance is canakinumab. 
Djelatna tvar je kanakinumab.
A murine antimurine IL-1 beta antibody had no undesirable effects on fertility in male or female mice (see section 5.3). 
Protutijelo na mišji IL-1 beta nije imalo neželjenih učinaka na plodnost mužjaka ili ženki miševa (vidjeti dio 5.3).
Treatment with Ilaris may result in dizziness/vertigo or asthenia (see section 4.8). 
Liječenje Ilarisom može rezultirati omaglicom/vrtoglavicom ili astenijom (vidjeti dio 4.8).
Patients taking canakinumab in Part II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032). 
Bolesnici koji su uzimali kanakinumab u drugom dijelu imali su za 64% smanjeni rizik od naglog pogoršanja bolesti u usporedbi s placebo skupinom (omjer hazarda 0,36; 95% CI: 0,17 do 0,75; p=0,0032).
The expression of hepatic CYP450 enzymes may be suppressed by the cytokines that stimulate chronic inflammation, such as interleukin-1 beta (IL-1 beta). 
Ekspresiju jetrenih CYP450 enzima mogu potisnuti citokini koji stimuliraju kroničnu upalu, poput interleukina-1 beta (IL-1 beta).
Two non-randomised HIDS/MKD patients aged > 28 days but < 2 years were included in the study and received canakinumab. 
Dva nerandomizirana bolesnika s HIDS/MKD-om u dobi od >28 dana ali <2 godine bila su uključena u ispitivanje i primala kanakinumab.
Tip the vial to ensure that the required amount of solution can be drawn into the syringe. 
Nagnite bočicu kako biste osigurali da se potrebna količina otopine može uvući u štrcaljku.
Although ≥ Grade 2 reductions in neutrophil count occurred in 6.5% of patients (common) and Grade 1 reductions occurred in 9.5% of patients, the reductions are generally transient and neutropenia-associated infection has not been identified as an adverse reaction. 
Iako su se smanjenja broja neutrofila ≥ stupnja 2 javila u 6,5% bolesnika (često), a smanjenja stupnja 1 u 9,5% bolesnika, smanjenja su općenito prolazna te infekcija povezana s neutropenijom nije utvrđena kao nuspojava.
The estimated steady state AUCtau was 636.7 ± 260.2 μg*d/ml. 
Procijenjeni AUCtau u stanju dinamičke ravnoteže bio je 636,7 ± 260,2 μg*d/ml.
Hold the syringe at a 90-degree angle and in a single, smooth motion, push the needle straight down completely into the skin. 
Držite štrcaljku pod kutom od 90 stupnjeva i jednim glatkim pokretom do kraja gurnite iglu okomito prema dolje u kožu.
The overall predicted mean (±SD) for Cmin,ss, Cmax,ss and AUC,ss4w were 14.7±8.8 μg/ml, 36.5 ± 14.9 μg/ml and 696.1 ± 326.5 μg*d/ml, respectively. 
Ukupne predviđene srednje vrijednosti (±SD) za Cmin,ss, Cmax,ss i AUC,ss4w bile su 14,7±8,8 μg/ml, 36,5 ± 14,9 μg/ml odnosno 696,1 ± 326,5 μg*d/ml.
A 6-year observational registry study was conducted to provide data on the long-term safety and effectiveness of canakinumab treatment in paediatric and adult CAPS patients in routine clinical practice. 
Provedeno je 6-godišnje opservacijsko ispitivanje u obliku registra (opservacijski registar) kako bi se dobili podaci o dugoročnoj sigurnosti i učinkovitosti liječenja kanakinumabom pedijatrijskih i odraslih bolesnika s CAPS-om u rutinskoj kliničkoj praksi.
Seventeen patients (including 6 patients under the age of 2 years) were evaluated, using weight-based starting doses of 2-8 mg/kg. 
Bilo je ocijenjeno sedamnaest bolesnika (uključujući 6 bolesnika mlađih od 2 godine) uz početne doze od 2-8 mg/kg temeljene na tjelesnoj težini.
Make sure all of the solution is in the bottom of the vial. 
13. Provjerite da je cjelokupna otopina na dnu bočice.
Disease activity was rated as absent or mild/moderate in more than 90% of patients at all post-baseline time points in the study, and median serological markers of inflammation (CRP and SAA) were normal (< 10 mg/litre) at all post-baseline time points. 
Aktivnost bolesti je bila ocijenjena kao odsutna ili blaga/umjerena u više od 90% bolesnika u svim ispitivanim vremenskim točkama nakon početka ispitivanja i srednja vrijednost seroloških upalnih markera (CRP i SAA) je bila normalna (<10 mg/litra) u svim ispitivanim vremenskim točkama nakon početka.
Turn the vial and syringe upside down and bring to eye level. 
Preokrenite bočicu sa štrcaljkom naopako i podignite je do razine očiju.
Allow to stand for about 15 minutes at room temperature to get a clear to opalescent solution. 
Pustite da odstoji oko 15 minuta na sobnoj temperaturi kako biste dobili bistru do opalescentnu otopinu.
In the long-term, open-label studies with dose escalation, events of infections (gastroenteritis, respiratory tract infection, upper respiratory tract infection), vomiting and dizziness were more frequently reported in the 600 mg or 8 mg/kg dose group than in other dose groups. 
U dugoročnim, otvorenim ispitivanjima s eskalacijom doze pojave infekcija (gastroenteritis, infekcija dišnog sustava, infekcija gornjeg dijela dišnog sustava), povraćanja i omaglice bile su češće u skupini koja je primala dozu od 600 mg ili 8 mg/kg nego u ostalim doznim skupinama.
What Ilaris contains 
Što Ilaris sadrži
The aim of the study was to assess efficacy, safety, and tolerability of canakinumab (150 mg or 2 mg/kg every 8 weeks) in patients with CAPS. 
Cilj ispitivanja bio je ocijeniti djelotvornost, sigurnost i podnošljivost kanakinumaba (150 mg ili 2 mg/kg svakih 8 tjedana) kod bolesnika s CAPS-om.
The safety and efficacy of Ilaris in SJIA patients under 2 years of age have not been established. 
Sigurnost i djelotvornost Ilarisa u bolesnika sa SJIA-om mlađih od 2 godine nije ustanovljena.
After 24 weeks, 71% (27/38) of patients who received the reduced dose (2 mg/kg every 4 weeks) and 84% (31/37) of patients who received the prolonged dosing interval (4 mg/kg every 8 weeks) were able to maintain inactive disease status for 6 months. 
Nakon 24 tjedna, 71% (27/38) bolesnika koji su primali smanjenu dozu (2 mg/kg svaka 4 tjedna) i 84% (31/37) bolesnika koji su imali produljeni interval doziranja (4 mg/kg svakih 8 tjedana) uspjelo je održati status neaktivne bolesti 6 mjeseci.
In clinical studies, CAPS, TRAPS, HIDS/MKD and FMF patients who have uncontrolled overproduction of IL-1 beta show a rapid and sustained response to therapy with canakinumab, i.e. laboratory parameters such as high C-reactive protein (CRP) and serum amyloid A (SAA), high neutrophil and platelet counts, and leukocytosis rapidly returned to normal. 
U kliničkim ispitivanjima bolesnici s CAPS-om, TRAPS-om, HIDS/MKD-om i FMF-om koji imaju nekontrolirano prekomjerno stvaranje IL-1 beta pokazuju brzi i održani odgovor na terapiju kanakinumabom, tj. povratak na normalne vrijednosti laboratorijskih parametara poput C-reaktivnog proteina (CRP) i serumskog amiloida A (SAA), visokog broja neutrofila i trombocita te leukocitoze.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti u skladu s lokalnim propisima.
If you received canakinumab while you were pregnant, it is important that you inform the baby's doctor or nurse before any vaccinations are given to your baby. 
Ako ste primili kanakinumab tijekom trudnoće, važno je da o tome obavijestite djetetovog liječnika ili medicinsku sestru prije nego
Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL1 beta gene, initiating a gouty arthritis attack. 
Drugi aktivatori prirođenog imunološkog sustava, kao što su endogeni agonisti receptora sličnih Tollu, mogu doprinijeti transkripcijskoj aktivaciji IL-1 beta gena te započeti napad uričnog artritisa.
Live vaccines: You are advised to avoid being vaccinated with a type of vaccine called a live vaccine while you are being treated with Ilaris. 
Živa cjepiva: preporučuje se da izjegavate cijepljenje vrstom cjepiva koje se naziva živim cjepivom dok se liječite Ilarisom.
• Patient Reminder Card 
• Kartica s podsjetnikom za bolesnika
Antibodies against Ilaris were observed in approximately 1.5%, 3% and 2% of the patients treated with Ilaris for CAPS, SJIA and gouty arthritis, respectively. 
Protutijela protiv Ilarisa uočena su u otprilike 1,5%, 3% i 2% bolesnika liječenih Ilarisom zbog CAPSa, SJIA te u 2% bolesnika liječenih Ilarisom zbog uričnog artritisa.
Macrophage activation syndrome in patients with Still's disease 
Sindrom aktivacije makrofaga u bolesnika sa Stillovom bolešću
Periodic fever syndromes Ilaris is used in adults and children aged 2 years and older to treat the following: - Cryopyrin-associated periodic syndromes (CAPS) - this is a group of auto-inflammatory diseases, which include: 
Ilaris se primjenjuje u odraslih osoba i djece u dobi od 2 i više godina za liječenje sljedećeg: periodičnih sindroma povezanih s kriopirinom (CAPS) - to je skupina autoinflamatornih bolesti koja uključuje:
Abnormal kidney function test results (creatinine renal clearance decreased, proteinuria). 
Poremećeni rezultati testa bubrežne funkcije (smanjeni bubrežni klirens kreatinina, proteinurija).
In a subset of young adult SJIA patients aged 16 to 20 years (n=31), the safety profile of canakinumab was consistent with what was observed in SJIA patients less than 16 years of age. 
U podskupini mladih bolesnika sa SJIA-om u dobi od 16 do 20 godina (n=31), sigurnosni profil kanakinumaba bio je u skladu s onim što je zabilježeno u bolesnika sa SJIA-om mlađih od 16 godina.
Immediately proceed to administering the injection. 
Odmah nastavite s primjenom injekcije.
Secondary endpoints, all based on week 16 results (end of Part II), included the proportion of patients who achieved a PGA score of < 2, the proportion of patients with serological remission (defined as CRP ≤ 10 mg/l), and the proportion of patients with a normalised SAA level (defined as SAA ≤ 10 mg/l). 
Sekundarne mjere ishoda, sve temeljene na rezultatima iz 16. tjedna (kraj II. dijela), uključivale su udio bolesnika koji su postigli PGA od <2, udio bolesnika sa serološkom remisijom (definirano kao CRP ≤10 mg/l) te udio bolesnika s normaliziranom razinom SAA (definirano kao SAA ≤10 mg/l).
The CAPS interventional trials with canakinumab included a total of 80 paediatric patients with an age range from 2 to 17 years (approximately half of them treated on an mg/kg basis). 
Intervencijska ispitivanja CAPS-a s kanakinumabom uključivala su ukupno 80 pedijatrijskih bolesnika u dobi od 2 do 17 godina (otprilike polovica njih bila je liječena na temelju mg/kg).
Using an 18 G or 21 G x 2 inch needle (or similar as available on the market) and a 1 ml syringe, carefully withdraw the required volume depending on the dose to be administered. 
Koristeći iglu od 18 G ili 21 G x 50 mm (ili sličnu, ovisno o tome što je dostupno na tržištu) i štrcaljku od 1 ml, pažljivo izvucite potreban volumen ovisno o dozi koja se primjenjuje.
Patients on urate lowering therapy (ULT) 
Bolesici na terapiji za snižavanje urata (ULT)
Patients with Still's disease may develop a condition called macrophage activation syndrome (MAS), which can be life-threatening. 
U bolesnika sa Stillovom bolešću može se razviti stanje koje se naziva sindrom aktivacije makrofaga, a koje može biti opasno po život.
The rate of adverse events in both treatment arms was similar to the rate seen in patients treated with canakinumab 4 mg/kg every 4 weeks. 
Stopa štetnih događaja u obje skupine liječenja bila je slična stopi u bolesnika liječenih kanakinumabom u dozi od 4 mg/kg svaka 4 tjedna.
Mean and median increases in alanine transaminase (ALT) of 3.0 U/l and 2.0 U/l, respectively, and in aspartate transaminase (AST) of 2.7 U/l and 2.0 U/l, respectively, from baseline to end of study were seen in the canakinumab-treated groups versus the triamcinolone acetonide-treated group(s), however the incidence of clinically significant changes (≥ 3 x the upper limit of normal) was greater for patients treated with triamcinolone acetonide (2.5% for both AST and ALT) compared with canakinumabtreated patients (1.6% for ALT and 0.8% for AST). 
Srednje povećanje alanin transaminaze (ALT) od 3,0 U/l i medijan povećanja od 2,0 U/l te srednje povećanje aspartat transaminaze (AST) od 2,7 U/l i medijan povećanja od 2,0 U/l, od početka do kraja ispitivanja, zabilježeno je u skupinama liječenim kanakinumabom u usporedbi sa skupinom (skupinama) liječenom triamcinolon acetonidom, međutim, incidencija klinički značajnih promjena (≥3 x gornja granica normale) bila je veća za bolesnike liječene triamcinolon acetonidom (2,5% i za AST i za ALT) u usporedbi s bolesnicima liječenima kanakinumabom (1,6% za ALT i 0,8% za AST).
Animal studies have shown that a murine anti-murine IL-1 beta antibody had no undesirable effects on development in nursing mouse pups and that the antibody was transferred to them (see section 5.3). 
Ispitivanja na životinjama pokazala su da protutijelo na mišji IL-1 beta nije imalo neželjenih učinaka na razvoj u mladunčadi miševa koja se doji te da se protutijelo prenijelo na njih (vidjeti dio 5.3).
In clinical studies, canakinumab has been safely administered with ULT. 
U kliničkim ispitivanjima kanakinumab se sigurno primjenjivao uz ULT.
Overall, the efficacy, safety and tolerability profile of canakinumab in elderly patients ≥ 65 years of age was comparable to patients < 65 years of age. 
Općenito je profil djelotvornosti, sigurnosti i podnošljivosti kanakinumaba u starijih bolesnika u dobi od ≥65 godina bio usporediv s onim kod bolesnika u dobi od <65 godina.
In active-controlled gouty arthritis trials, there was a mean increase in triglycerides of 33.5 mg/dl in canakinumab-treated patients compared with a modest decrease of -3.1 mg/dl with triamcinolone acetonide. 
U aktivno kontroliranim ispitivanjima uričnog artritisa došlo je do srednjeg povišenja triglicerida od 33,5mg/dl kod bolesnika liječenih kanakinumabom, u usporedbi sa skromnim smanjenjem od -3,1 mg/dl s triamcinolon acetonidom.
Remove the caps from the Ilaris and water vials. 
Uklonite kapice s bočice Ilarisa i bočice s vodom.
Increases in uric acid level (0.7 mg/dl at 12 weeks and 0.5 mg/dl at 24 weeks) were observed after canakinumab treatment in comparative trials in gouty arthritis. 
Povišenja razine mokraćne kiseline (0,7 mg/dl nakon 12 tjedana i 0,5 mg/dl nakon 24 tjedna) bila su uočena nakon liječenja kanakinumabom u komparativnim ispitivanjima uričnog artritisa.
9/l) and transient decreases in platelet counts were observed at a higher incidence (12.7%) with canakinumab in the active-controlled clinical studies versus the comparator (7.7%) in gouty arthritis patients. 
9/l) i prolazna smanjenja broja trombocita zabilježena su uz veću incidenciju (12,7%) s kanakinumabom u aktivno kontroliranim kliničkim ispitivanjima nego s komparatorom (7,7%) kod bolesnika s uričnim artritisom.
TRAPS, HIDS/MKD and FMF The efficacy and safety of canakinumab for the treatment of TRAPS, HIDS/MKD and FMF were demonstrated in a single, pivotal, phase III, 4-part study (N2301) consisting of three separate disease cohorts. 
TRAPS, HIDS/MKD i FMF Djelotvornost i sigurnost kanakinumaba za liječenje TRAPS-a, HIDS/MKD-a i FMF-a dokazane su u jednom ključnom četverodijelnom ispitivanju faze III (N2301) koje se sastojalo od tri zasebne kohorte prema bolesti.
Higher proportions of patients had normalised SAA (≤ 10 mg/l) at week 16 with canakinumab treatment compared to placebo in all three cohorts, with a statistically significant difference observed in TRAPS patients (see Table 3 with study results below). 
Viši udjeli bolesnika imali su normalizirani SAA (≤10 mg/l) u 16. tjednu uz liječenje kanakinumabom u usporedbi s placebom u sve tri kohorte, uz statistički značajnu razliku opaženu u bolesnika s TRAPS-om (vidjeti Tablicu 3 s rezultatima ispitivanja u nastavku).
Canakinumab binds to serum IL-1 beta. 
Kanakinumab se veže za IL-1 beta u serumu.